To print: Select File and then Print from your browser's menu

Title: Glycation Levels Could Affect Progression Of Osteoarthritis

URL: http://www3.interscience.wiley.com/cgi-bin/abstract/88010819/START

Arthritis & Rheumatism, 2001; 44: 2562-2571. "Age-related decrease in susceptibility of human articular cartilage to matrix metalloproteinase-mediated degradation: The role of advanced glycation end products"
12/07/2001 08:02:00 AM
By Elda Hauschildt

Levels of glycation could affect the progression of disease in patients with osteoarthritis and rheumatoid arthritis. Aged cartilage is less sensitive than young cartilage to matrix metalloproteinases (MMPs), Dutch researchers say. They report finding that increased cartilage advanced glycation end-products (AGEs) result in decreased cartilage degradation by MMPs from synovial fluid in a study of donors aged from 33 to 83 years. "Progressive destruction of articular cartilage is a hallmark of osteoarthritis and rheumatoid arthritis," say investigators from the Gaubius Laboratory in Leiden and the University Medical Centre in Utrecht. They studied the effect of age-related accumulation of AGEs on cartilage susceptibility to proteolytic degradation by MMPs in synovial fluid by incubating cartilage from both osteoarthritis and rheumatoid arthritis patients. Researchers assessed tissue degradation by colorimetric measurement of glycosaminoglycan release. They then related the degradation to the level of AGEs in cartilage from donors of different ages and in cartilage with in vitro-enhanced AGE levels. "A strong correlation was found between the age-related increase in pentosidine and the decrease in MMP-mediated tissue degradation," they concluded. "Multiple regression analysis showed pentosidine to be the strongest predictor of the decreased glycosaminoglycan release. "Age did not contribute." Investigators point out they found that decreased MMP-mediated glycosaminoglycan release was proportional to increased pentosidine levels after in vitro enhancement of glycation for both osteoarthritis and rheumatoid arthritis patients.

http://www3.interscience.wiley.com/cgi-bin/abstract/88010819/START

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.